192. Cockayne syndrome
[
4 clinical trials,
7 drugs（DrugBank:
3 drugs),
1 target gene / 43 target pathways ]
Searched query = "Cockayne syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900026719 | 2019-11-01 | 21 October 2019 | Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome | Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome | Cockayne's syndrome | test group:Vitamin C and Quercetin; | The First Medical Center of PLA General Hospital | Not Recruiting | 6 | 13 | Both | test group:20; | Phase 0 | China | |
| 2 | NCT02960997 | May 2016 | 7 October 2019 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus, 2%;Drug: Vehicle | Stanford University | Not recruiting | 4 Years | N/A | All | 8 | Phase 2 | United States | |
| 3 | NCT03016715 | May 2016 | 16 December 2017 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus 2%;Drug: Vehicle | Premier Specialists, Australia | Recruiting | 5 Years | N/A | All | 8 | Phase 2 | Australia | |
| 4 | NCT01142154 | June 2010 | 19 February 2015 | Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome | A Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne Syndrome | Cockayne Syndrome | Drug: Prodarsan | DNage B.V. | Not recruiting | 2 Years | 10 Years | Both | 5 | Phase 1/Phase 2 | United States |